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This knowledge-based activity is targeted for all pharmacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

and withdrawal concerns to reduce the negative effects
elderly patients may experience with long-term use.
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Objectives
After completion of this program, the reader should be able
to:
1. Explain how benzodiazepines differentially affect the
elderly population in terms of pharmacokinetics and
pharmacodynamics.
2. Discuss specific adverse effects of benzodiazepines
in the elderly population and how these adverse effects impact quality of life.
3. Identify patients who are at highest risk of adverse
effects with benzodiazepine use.
4. Describe symptoms of and possible treatments for
patients experiencing withdrawal from benzodiazepines.
5. Identify ways a pharmacist can improve medication
management in the elderly population.
Abstract
Benzodiazepines remain a commonly prescribed medication
in the United States, and the high usage of this drug class is
especially a concern in the elderly population for several reasons. First, elderly patients metabolize drugs differently,
leading to varying responses. A~e-related changes also have
a significant impact on the effects of benzodiazepines. Second, elderly patients are more likely to be taking multiple
centrally-acting drugs, which can further exacerbate negative
effects. In regard to long-term benzodiazepine use, elderly
patients experience an increased risk of cognitive impairment, motor vehicle accidents, decline in physical performance, falls and subsequent fractures, and sleep disturbances.
Withdrawal is also a significant concern with long-term benzodiazepine treatment, which can lead to rebound symptoms
in addition to mood swings, tremor, headache and loss of appetite. A taper of less than six months is recommended when
discontinuing benzodiazepines after use longer than the recommended three month duration of treatment. Pharmacists
can have a substantial impact in reducing the detrimental
effects of long-term use of benzodiazepines by aiding in the
tapering process, as well as identifying inappropriate prescribing and use of benzodiazepines in the elderly population. Overall, pharmacists should be knowledgeable on the
appropriate use of benzodiazepines, associated side effects
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Introduction
Despite the potentially detrimental effects of benzodiazepine
use, benzodiazepines remain a commonly prescribed medication in the United States. In 2012, Ohio prescribers wrote
41.3 prescriptions for benzodiazepine medications per 100
people, ranking Ohio 20th compared to other states.1 Ohio is
slightly above the national rate of 37.6 prescriptions per 100
people. The high usage of benzodiazepines is especially a
concern in the elderly population, in part because elderly
patients respond to and metabolize drugs differently. Even if
a patient has been on a benzodiazepine for many years, it
may begin to have different or more severe adverse effects as
the patient ages. Elderly patients, generally defined as 65
years of age and older, are also more likely to be taking several medications, which may include other centrally-acting
drugs. The combination of these factors leads to an increased
risk of cognitive impairment, motor vehicle accidents, decline
in physical performance, falls and subsequent fractures, and
sleep disturbances in the elderly population.
Benzodiazepines are included on the American Geriatric Society's Beers Criteria, which notes that elderly patients are
known to have higher sensitivity to and slower metabolism
of long-acting benzodiazepines, increasing the risk of negative effects.2 Studies have found these effects can also be seen
with short-acting formulations .3 It can be concluded that if
detrimental effects are seen with both short-acting and longacting formulations of benzodiazepines, then these effects
can also be observed with the intermediate-acting medications (Table 1).4 The Beers Criteria recommendation for benzodiazepine use is classified as 'strong,' meaning that the
burdens/risks of use outweigh the potential benefits.2 Although benzodiazepines may still be an appropriate option in
some instances, per the Beers Criteria their use is not
recommended in the elderly to treat insomnia, agitation or
delirium. Discontinuation of this class of drugs has been associated with some improvement in their negative effects,
especially those effects relating to cognition; however, there
are still lasting implications with long-term use. The withdrawal process and associated symptoms are also significant,
owing to the addictive properties and dependency effects of
this class of drugs.s As pharmacists, it is important to recognize how these drugs may affect elderly patients differently

THE PHARMACY AND WELLNESS REVIEW

Summer 2015 Volume 6. Issue 3

The Effects of Long-Term Benzodiazepine Use and Withdrawal in the Elderly

Geriatrics

Table 1. Commonly Prescribed Benzodiazepines.

Short-acting*

•
•

Midazolam (Versed™)
Triazolam (Halcion™)

Long-acting*

Intermediate-acting*

•
•
•
•
•
•

Alprazolam (Xanax™)
Conazepam (Klonopin ™)
Diazepam (Valium™)
Lorazepam (Ativan™)
Oxazepam (Serax™)
Temazepam (RestorW"')

•
•

Chlordiazepoxide (Librium TM)
Flurazepam (Dalmane™)

*classification based on half-life of active components 4
and to manage these medications accordingly. Pharmacists
have an essential role in identifying elderly patients being
newly prescribed or currently taking long-term benzodiazepines who may be candidates for other treatment options,
making alternative medication recommendations to physicians and assisting patients during the withdrawal process.
Typical and appropriate indications for benzodiazepine use
in the elderly include anxiety, panic disorder, sleep disorder
and adjustment disorder which are similar to the indications
for use in the nonelderly population. However, in some instances such as in a patient who is refractory to standard
treatment, benzodiazepines may be appropriately used for
short-term treatment of insomnia or agitation even though
the recommendation from the Beers Criteria is to avoid use
for these indications. 2 Central nervous system (CNS) depression is a typical side effect of benzodiazepines for all age
groups. Of significance is that within the older population
these side effects are observed more frequently and to a
greater extent, and some negative outcomes such as falls,
fractures and a decrease in physical performance are unique
to the elderly demographic. In the elderly population, these
side effects can have substantial implications on the patient's
quality of life, autonomy and independence. This increased
severity of side effects is due primarily to pharmacodynamic,
rather than pharmacokinetic, changes in the CNS and brain
that occur naturally with aging and lead to a greater sensitivity to benzodiazepines. 6·7 In fact, elderly patients generally
require lower doses of benzodiazepines, corresponding to
lower blood concentrations to achieve the effect of sedation,
highlighting the increased sensitivity displayed in older patients.a The pharmacokinetic changes that occur include
changes in the elimination and distribution of benzodiazepines in the aging brain; but, more importantly, the pharmacodynamic changes in the CNS make the receptors more
sensitive to the drug.7 The target for benzodiazepines to produce their CNS effects are the gamma-aminobutyric acid-a
(GABAa) receptors, which are ligand-gated chloride channels. The binding of the benzodiazepine causes the channel
to open and results in an influx of chloride, which decreases
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neuronal firing.9 The GABAa receptor is made up of several
subunits, which contributes to why there are a variety of
symptoms associated with this drug class in all patient age
groups. The increase in severity of side effects in the elderly
may be so extreme for benzodiazepines in particular because
GABAa receptors are widely distributed throughout the CNS
in the spinal cord, cortex, cerebellum, and limbic system, and
the distribution of the GABAa receptors changes with age,
altering the excitability of the brain.6,9 With the high number
of receptors and an increased sensitivity with the aging process, many of the effects seen in a younger person will be
exaggerated in the elderly such as greater sedation, less coordination of movement and less inhibition.7 Changes in psychomotor abilities, reaction time, delirium, coordination and
attention are also potential effects of benzodiazepine use in
the elderly.10.11
Cognitive Impairments
The use of benzodiazepines can negatively impact cognition
or exacerbate normal age-related cognitive decline in elderly
patients. However, the length of time the patient is taking the
medication is a significant predictor of cognitive decline.12
Associated risks are increased with the long-term use of benzodiazepines even in those patients who used benzodiazepines chronically and have already successfully discontinued
therapy. The length of time a patient has been taking benzodiazepines is a significant predictor of cognitive decline and
has been shown to have a greater effect on sustained cognitive impairment compared to the dose alone. Evidence supporting the long-term implications on cognition is varied.
Not all patients taking therapeutic doses of benzodiazepines
long-term will experience these cognitive and memory impairing effects, or the effects they do experience may be minimal.12·13 However, several studies have found that cognitive
impairment does occur with chronic benzodiazepine use.10
Central nervous system depression and decline in cognition,
alertness and decision-making capacity are all recognized
side effects of therapy. Notable short-term effects include
anterograde amnesia, or difficulty learning new information,
a decrease in mental alertness and the capacity to coordinate
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fine movements.13 Long-term users tend to develop some
tolerance to the sedative effects (for example, the drowsiness
is less severe over time when compared to initiation of therapy), but effects on memory and cognition continue throughout use. Patients taking benzodiazepines chronically may
also struggle to process information quickly and sustain attention on a task for an extended amount of time, as well as
have difficulty with visuospatial skills. These effects are more
detrimental in the elderly population in terms of severity and
persistence of symptoms, even after the medication has been
discontinued. These negative cognitive effects impact the
elderly patient's quality of life, memory and independence.
The negative effects of benzodiazepine use in the elderly may
extend beyond the duration of therapy to a greater extent
than in the nonelderly population. Cognitive impairment was
found to persist for at least six months after discontinuation,
in comparison to patients who had not been on benzodiazepines, suggesting that this class of drugs may cause functional changes in the brain that are permanent or at least slowly
reversible.10 While there is strong evidence that benzodiazepines have negative effects on cognitive performance while
using the medication, not all studies support the same
conclusion, and research is inconclusive as to how long the
damage lasts once the medication is discontinued. A metaanalysis involving 13 studies that lasted for a t least one year
and were published between 1980 and 2000 examined the
effects of long-term benzodiazepine use on cognition.5 The
authors were not able to make conclusions about whether or
not the cognition and memory impairment of benzodiazepines extended beyond therapy termination due to the heterogeneity and limited number of studies in the meta-analysis.
The study points to the complicated nature of assessing
cognition considering the impact of test-induced anxiety in
patients who may already be prone to anxiety. In practice,
however, the most conservative treatment plan should be
used if possible; the potential risk of lingering CNS effects
impacting cognition is high enough to discourage long-term
use of benzodiazepines if another treatment of equal efficacy
is available.
Motor Vehicle Accidents
Decreased alertness, altered decision-making capacity and
changes in perception are cognitive-based factors that contribute to an increased risk of motor vehicle accidents in elderly patients taking benzodiazepines.14,15Reaction time is
another critical factor that is negatively impacted by benzodiazepine use.14 Crashes that involve elderly drivers are generally related to perception and cognitive difficulties, such as
crossing the center into the adjacent lane, inappropriate
judgment of gaps between vehicles and not giving way to
other vehicles. Although studies still show that younger drivers are more likely to be in car accidents than older drivers,
the risks are highest in those ages 18 to 25 years and ages 65
years and greater.14,15 Importantly, in the 65 years of age and
greater population, there is an even higher risk of accidents
in those taking benzodiazepines. 14 In fact, benzodiazepines
are commonly found at detectable blood levels in people involved in car accidents when it is suspected that they were
impaired due to substances. This finding includes both ben-

zodiazepines being used therapeutically and as drugs of
abuse, meaning it includes those taking benzodiazepines for
reasons other than prescribed or at doses higher than prescribed. As expected, the risks associated with benzodiazepines and traffic accidents increase with the size of the dose,
the number of benzodiazepines being used, combinations
with other CNS depressants (e.g., alcohol) and how long the
driver has been taking the medication. This may even suggest that tolerance develops to the side effects of the medication with chronic use compared to the cognitive changes
seen initially in a patient on a benzodiazepine.16
Physical Disability
Benzodiazepines increase the risk for mobility impairments
and difficulties with completing daily tasks such as bathing,
dressing and feeding.3,17 The decline in physical performance
is due to the effects on the patient's neuromuscular processing and psychomotor abilities, as well as the sedation,
that is caused by benzodiazepine use.3 Again, there is some
natural risk of declining mobility and ability to perform daily
tasks associated with aging, but benzodiazepine use in the
elderly has been found to increase the risk for physical disability by 23 percent. Specifically, women are at a greater risk
for these changes than elderly men likely due to poorer muscle strength and control initially.J.1 7 Although it was previously believed that these physical impairments would be
lessened if the patient was prescribed short-acting rather
than long-acting formulations due to the shorter half-life, not
all studies support this theory.3 Short-acting benzodiazepines are more likely to be taken in higher doses, therefore
increasing total drug exposure and leading to higher peak
concentrations. Overall, risk for physical disability is greatest
in patients using higher doses and long-term therapy, defined as three years or more in this study specifically.17 Unfortunately, the negative effects on physical functioning can
still be seen even at low doses of benzodiazepines.3 Although
higher drug exposure does tend to lead to more detrimental
effects, there are still many interindividual differences that
allow low doses to have an equally negative impact in some
patients. One study examined whether the physical disability
was resulting from benzodiazepine use itself or from a shift
to a less active lifestyle due to the sedative effects of the
medication. It was concluded that activity level was not a
confounder in decreasing physical performance, so it can be
concluded that the effects of the benzodiazepine were likely
the reason for the decline in physical function.
Fall Risks
Benzodiazepines are one of many drug classes that pose a fall
risk in the elderly population owing to an increase in the
risks associated with falls, such as impaired muscle strength,
coordination and balance. Although risk of falls increases
naturally with aging, benzodiazepine use can exacerbate this
risk. In a study, handgrip strength and balance were used as
indicators to assess fall risk in elderly patients taking the
intermediate-acting benzodiazepine, temazepam, or one of
two Z-drugs, zolpidem or zolpiclone, which work similarly to
benzodiazepines.1s Successful discontinuation from longterm benzodiazepine use led to an improvement in handgrip
strength and balance in elderly patients. The findings showed
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that benzodiazepine usage does play a significant role in fall
risk, and the incidence among some elderly patients may be
due to more than typical age-related decline. This fact increases the importance of identifying patients who could be
switched to an alternate therapy. As women are at a greater
risk of physical disability than men, as noted earlier, this also
places them at a greater risk for falls than men. Considering
overall health care economics, benzodiazepines are relatively
inexpensive medications, but the financial burden of treating
falls and fall-related injuries attributed to benzodiazepine
use can be significant.

Fractures
In the elderly population, fractures and other musculoskeletal injuries are often sustained due to falls. As expected, there
is an increase in fractures in long-term benzodiazepine users.19 Similar to the research regarding physical disability in
general, there was not a difference in fractures sustained due
to benzodiazepines based on whether they were short-acting
or long-acting products.3,19 In a study that compared the
United States with several large European countries, the
overall average of hip fractures that could be attributed, at
least in part, to benzodiazepine use was 1.8 to 8.2 percent.19
Although this is a large range, even the most conservative
finding of 1.8 percent shows that fractures as a consequence
of benzodiazepine use are still meaningful when considering
the other age-related and drug-related causes for fractures
and falls in the elderly population and the individual impact a
fracture has on a patient's quality of life.
Sleep Problems
Sleep disturbances are a frequent reason for an elderly patient to be prescribed a benzodiazepine, yet approximately
80 percent of the elderly population who are taking benzodiazepines report having problems with sleep.zo.z1 Despite the
indication for benzodiazepines to help with sleep, a study
found that overall sleep quality declined in adults 65 years of
age or older when using benzodiazepines long-term.zo
Though these medications are generally only recommended
to be used for three months, regardless of age and indication,
most patients use them for much longer. Another metaanalysis that examined 45 randomized controlled trials testing benzodiazepine use for insomnia found that although
benzodiazepines are slightly beneficial in increasing the
length of time a patient is asleep, there are not any significant
benefits on the length of time for sleep onset, and there are
additional negative effects associated with their use.z1 The
most common negative effects patients reported in the studies included being drowsy during the day, dizziness and
lightheadedness. For long-term users of benzodiazepines, the
risks and negative effects associated with usage outweigh the
potential benefit for sleep.
Like most of the effects discussed previously, sleep disturbances are seen more significantly in the elderly population
due to the negative impacts of benzodiazepine use being
compounded with natural, age-related decline in sleep quality.zo Importantly, not only did the benzodiazepine users have
poorer sleep quality than nonusers, but those taking benzodiazepines long-term had the worst sleep quality overall
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when compared to those who only took the medications
short-term. This result is not often seen in initial clinical trials assessing medications' effects on sleep because research
is often not conducted for a long enough time to appropriately examine the effects of the drug long-term, which is how
the drugs are often used in practice.

Withdrawal
Although cognitive impairment, physical disabilities and
sleep problems are possible adverse effects of taking benzodiazepines, withdrawal is perhaps the biggest controversy
pertaining to their use. However, due to prescribing traditions and patient preference, long-term use of benzodiazepines occurs in more than one-third of patients.zz-z4 This is a
cause for alarm due to the risks of adverse effects and continued efficacy. A study by Salzman and colleagues found the
memory and cognitive functioning of elderly nursing home
patients improved in those tapered off benzodiazepines
when compared to those who remained on the medications.zs The recommendation for those patients on benzodiazepines for longer than three months is to gradually reduce
the dosage through a tapering schedule.z6 This taper should
last less than six months or else this process occupies all of
the patient's focus.zs Before interrupting benzodiazepine use,
health care providers should ensure the patient is in good
health, and that he or she is fully educated about the possible
recurrent, rebound or new symptoms that can occur.zz.z7
The original indication for benzodiazepine use, whether insomnia or anxiety, may worsen to pretreatment levels during
the tapering period.Z 4 In some cases, the symptoms may elevate beyond pretreatment levels and is considered a rebound
symptom. Therefore, it is necessary to evaluate the patient's
underlying medical or psychiatric conditions before ceasing
benzodiazepine use.zz Symptoms of withdrawal and rebound
are enhanced with the use of short-acting benzodiazepines
due to their short half-life, rapid elimination and increased
dosing frequency (Table 1).Z4 The short-acting agents, midazolam and triazolam, are generally not used throughout the
day, so the withdrawal and rebound may not be as evident,
although rebound effects have been reported with the use of
triazolam.zs Alprazolam and oxazepam, which are considered
intermediate-acting agents with half-lives of about three to
20 hours, may be dosed more frequently and are associated
with symptoms of withdrawal and rebound if discontinued
abruptly. z7 Rebound symptoms may occur after long-term
use of any benzodiazepine, and may require a nonbenzodiazepine substitute for those experiencing exacerbations of
their sleep disorders or anxiety. Selective serotonin reuptake
inhibitors (SSRls) or tricyclic antidepressants (TCAs) are
acceptable alternatives for those with rebound depressive
symptoms, and melatonin agonists, such as ramelteon
(Rozerem®), may aid in sleep disorders. nzs.z9,30 Psychological support, spanning from encouragement to cognitive or
behavioral therapy, should also be provided for those
patients in need of anxiety management and should be
available long after tapering is complete.z3 Decreased use of
caffeine and alcohol, along with proper sleep, hygiene and
relaxation techniques, may be enough to help insomnia without the need to initiate medications. Overall, the entire health
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care team needs to be prepared to help the patient pharmacologically and nonpharmacologically with any issues resulting from rebound symptoms throughout tapering.
Along with possible rebound symptoms, withdrawal
symptoms add to the difficulty of the benzodiazepine tapering process. The most frequent withdrawal symptoms include insomnia, anxiety, mood swings, myalgia/muscle
twitching, tremor, headache, nausea/vomiting, loss of appetite, hypersensitivity to noise, changes in movement and feelings of unreality.29 Throughout the withdrawal process these
symptoms wax and wane and can differ in severity for each
patient. 23 The 20-item Benzodiazepine Withdrawal Symptom
Questionnaire or the Physician Withdrawal Checklist can be
used to measure patient's symptoms during each case of
withdrawal.3 1 Due to these occasionally unbearable symptoms, slow dosage reduction and proficient psychological
support are necessary for the success of benzodiazepine tapering.23 Abrupt withdrawal could cause convulsions, panic
reactions and acute psychotic states. The occurrence of seizures upon withdrawal, although rare, is more likely in patients with an underlying seizure disorder or when receiving
concomitant medications that may lower the seizure threshold.27 As previously mentioned, tapers should last less than
six months, but this process should be adapted to each individual patient based on lifestyle, personality, environment
and available support. 23,2s
Dosage reduction is an individualized process based on each
patient's characteristics.23 Those on higher doses of benzodiazepines can tolerate larger dosage cutbacks, and the
majority of patients take therapeutic doses less than 20 mg
diazepam or equivalent daily. The usual dose of diazepam for
the treatment of anxiety is 2 mg to 10 mg two to four times
daily if needed, allowing for a maximum dose per day of 40
mg.32 Generally, it is recommended to reduce the dose by 10
percent to 25 percent each week.22Reductions of 1 mg diaze-

pam every one to two weeks are usually well tolerated.22 Yet,
if the patient is taking 40 mg of diazepam daily, an initial reduction of 2 mg every one to two weeks may be more appropriate, as the patient is considered to be on a higher dose.
Once the daily dosage reaches 4 mg to 5 mg, decreasing by
0.5 mg may be preferred to prevent negative effects. In order
to improve adherence and patient's peace of mind, a written
withdrawal schedule should be provided rather than just
verbal instructions. A chart to check off days and doses is
helpful for patients to stay goal-oriented. These schedules
will be flexible to changes upon the appearance of any problems, such as severe symptoms or stressors. If at any point in
the process withdrawal symptoms become notably severe,
the tapering can be slowed. Diazepam, an intermediateacting agent, is the easiest benzodiazepine for tapering since
it has multiple available strengths including 10 mg, 5 mg and
2 mg tablets. Therefore, many patients are switched from
their original benzodiazepine medication to an equivalent
diazepam dosage (Table 2) especially within one month of
complete discontinuation. 22 .23,27 Keep in mind, psychological
and anxiety management should be provided throughout the
entire dosage reduction process.
Benzodiazepine withdrawal is a very complex and taxing
process for patients. As a result, it is recommended any patient dependent on benzodiazepines and going through withdrawal attends self-help groups run by ex-benzodiazepine
users, psychologists, counselors or trained paramedical
workers .23 Along with these group meetings, it is important
for the patients to receive individualized psychological care
in which they can confront personal or social problems underlying their anxiety and need for long-term benzodiazepine use. Involvement of family members in this practice is
significant because it allows the patient to feel supported and
to expose themselves to others, which increases their confidence and self-esteem. These individuals need to be highly
self-motivated in order to succeed with the tapering regi-

Table 2. Benzodiazepine Equivalent Doses.22,23,27

Benzodiazepines
Alprazolam (Xanax)

Oral Doses (mg) Equivalent to 10 mg Diazepam
0.5 -1

Chlordiazepoxide(Librium)

25

Clonazepam (Klonopin)

0.5

Clorazepate (Tranxene)

15

Diazepam (Valium)

10

Flurazepam (Dalmane)

30
1-2

Lorazepam (Ativan)
Oxazepam (Serax)

20

Quazepam (Doral)

20

Temazepam (Restoril)

20
0.25 - 0.5

Triazolam (Halcion)
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mens. As stated earlier, it is important to inform patients of
the possible problems that can occur during withdrawal and
ensure they are dedicated and willing to fully adhere to the
program. Health care providers for any patients going
through withdrawal or abusing benzodiazepines can educate
them regarding the advantages of withdrawal and establish
trust with them each step of the way.
Even though psychological support is available to patients
throughout benzodiazepine tapering, the withdrawal symptoms may be perceived as too difficult to handle. Several
medications have been evaluated as possible withdrawal and
symptom-relief aids in order to allow more patients to be
successful. Flumazenil is a benzodiazepine partial agonist
which normalizes receptor function and has been evaluated
for decreasing patients' craving and relapse rates and even
reducing the hostile and aggressive behaviors that are often
associated with withdrawal.33.3 4 A randomized, placebocontrolled study found that when compared to oxazepam,
flumazenil can counteract benzodiazepine effects and control
benzodiazepine withdrawaJ.33 Topiramate and carbamazepine, both anticonvulsants, have also been investigated in the
treatment of withdrawal symptoms and possibly relapse prevention.ls However, none of these medications have been
found to be fully successful in preventing benzodiazepine
withdrawal.
Role of the Pharmacist
Long-term use of benzodiazepines can lead to many adverse
effects, cognition issues and withdrawal symptoms. As one of
the most accessible health care providers, pharmacists can
have significant impact by aiding patients throughout this
complicated and difficult process. First, pharmacists in all
institutions and fields of pharmacy can identify elderly patients taking long-term benzodiazepines and use their professional judgment and knowledge to evaluate if the benefits
outweigh the risks for each individual patient. Community
pharmacists can assist in drug adherence and patient education by identifying potential drug interactions or adverse
reactions, supplying weekly pill dispensers or other compliance aids and administering information about specific
drugs.36 However, the pharmacist's responsibility expands
far beyond the patient. Pharmacists are in a good position to
communicate with prescribers in both the inpatient and
community settings to determine if patients could be
switched to another less risky therapy to treat their condition. Also, pharmacists should educate other health care professionals and ensure benzodiazepines are being prescribed
only for appropriate conditions when other options are not
available. Additionally, information should be exchanged
between pharmacists and physicians about medication reviews, prescribing committees, compiling drug formularies,
dose reduction regimens and possible ways to deal with benzodiazepine withdrawal.
Conclusion
Benzodiazepines are a commonly prescribed class of
medications in the elderly for anxiety and insomnia. However, long-term use of this class of medications is associated
with detrimental effects including cognitive impairment,
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sleep disturbances and physical disabilities. These drugassociated effects can lead to an increase in motor vehicle
accidents in the elderly patient population as well as an increased fall risk leading to more fractures and a decreased
quality of life. Withdrawal is one of the greatest issues with
Jong-term benzodiazepine treatment which can lead to rebound symptoms plus mood swings, tremor, headache, loss
of appetite and more. A taper of less than six months is recommended when discontinuing long-term benzodiazepine
use. Pharmacists can be beneficial during the tapering process, but also have the professional responsibility to identify
inappropriate prescribing and use of benzodiazepines in the
elderly population, which could circumvent many of these
issues altogether. Overall, the continued use of benzodiazepines in this patient population requires pharmacists to stay
updated on appropriate indications, side effects and withdrawal concerns as well as educate other health care professionals when necessary.
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Assessment Questions
l.

Why is the high usage of benzodiazepines especially a
concern in the elderly population?
A. Elderly patients respond to and metabolize
benzodiazepines differently.
B. Elderly patients are more likely to be taking
multiple medications, which may include other
centrally-acting ones.
C. Benzodiazepines, as a class, are more expensive
compared to other medications with similar
indications.
D. Two of the above are correct.

2.

According to the Beers Criteria, which is not a recommended indication for benzodiazepine use in elderly
patients?
A. insomnia
B. anxiety
C. panic disorder
D. Two of the above are correct.

3.

The increase in the severity of negative side effects with
benzodiazepine use in the elderly population is primarily
because of _ _ changes.
A. pharmacokinetic
B. pharmacogenomic
C. pharmacodynamic
D. pharmacoeconomic

4.

When considering the impact of benzodiazepines on
cognition, which is true?
A. Negative effects may extend beyond the
duration of therapy.
B. Dose is a greater predictor of negative cognitive
effects than the length of therapy.
C. Both A and Bare correct.
D. Neither statement is correct.

5.

In regard to benzodiazepines and physical function,
which is true?
A. Women are at a higher risk to suffer from a
decline in physical function and fractures.
B. Negative effects on physical function are not
seen with short-acting benzodiazepines.
C. The sedative effects of benzodiazepines decrease the activity level and lead to a decline in
physical function.
D. Two of the above are true.

6.

Although typically used much longer, the recommended
length of time for using benzodiazepines is _ _ __
A. Six weeks
B. Three months
C. No more than one year
D. There is no recommended length of time;
long-ter m use needs to be monitored.

7.

When considering the impact of benzodiazepine use on
motor vehicle accidents, which is true?
A. Benzodiazepines can have detrimental impacts
on driving only when used abusively.
B. Due to benzodiazepine use (along with other
sedative substances), elderly drivers are the
most likely to be involved in a motor vehicle
accident compared to other drivers.
C. Benzodiazepine use can impair reaction time
and alertness of an elderly driver.
D. Benzodiazepines have not been found to have a
significant impact on motor vehicle accidents.

8.

The taper schedule for benzodiazepines should be no
longer than:
A. Two months
B. Four months
C. Six months
D. One year

9.

In regard to the tapering process, the recommended dosage reduction ofbenzodiazepines per week is:
A. 10-25%
B. 5-10%
c. 25-30%
D. 15-35%

10. The benzodiazepine partial agonist that has been evaluated for decreasing patient's craving and relapse rates,
normalizing benzodiazepine receptor function and even
reducing hostile and aggressive behavior often associated with withdrawal is:
A. oxazepam
B. topiramate
C. carbamazepine
D. flumazenil
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The program objectives were clear.
The program met the stated goals and objectives:
1. Explain how benzodiazepines differentially affect the elderly population in terms of pharmacokinetics and pharmacodynamics.
2. Discuss specific adverse effects of benzodiazepines in the elderly population and how these adverse effects impact quality of life.
3. Identify patients who are at highest risk of adverse effects with benzodiazepine use.
4. Describe symptoms of and possible treatments for patients experiencing withdrawal from benzodiazepines.
5. Identify ways a pharmacist can improve medication management in
the elderly population.
The program met your educational needs.
Content of the program was interesting.
Material presented was relevant to my practice.
Audio/visual and/or printed materials aided the learning process.
The program used effective teaching/learning methods.
The learning assessment activities were appropriate.
The program showed good objectivity and no commercial bias.
Would you recommend this program to a colleague?
What was the most valuable part of this program?
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Based on what you have learned what one change do you plan to make in your practice? - -- - - - -- - - --

The speaker was well prepared and knowledgeable about the topic.
The quality of the speaker was excellent.
The speaker provided adequate time for questions.
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Answers to Assessment Questions-Please Circle Your Answer
3. A B C D
5. A B C D
7. A B C D
9. A B C D
4.

A B C D

6.

A B C D

Any questions/comments regarding this continuing education program can
be directed to Lauren Hamman, Advanced Administrative Assistant for
the Office of Continuing Education (email: l-hamman@onu.edu, phone
419-772-2280).
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